Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Science from our Sisters

Virginia Hughes  |  Issue: September 2007  |  September 1, 2007

Benefit of Methotrexate as Adjunctive Treatment for Giant Cell Arteritis Confirmed

A study in the August issue of Arthritis & Rheumatism (2007;56:2789-2797) looked at individual patient data from three placebo-controlled trials testing the effectiveness of methotrexate (MTX) as an adjunctive treatment for giant cell arteritis (GCA). This meta-analysis found that, when given in addition to standard corticosteroid treatment, MTX lowers both the risk of GCA relapse and the amount of corticosteroids needed.

Corticosteroids like prednisone are currently the primary option for treating GCA, a vascular disease characterized by inflammation of large arteries, usually in the head, that plagues fewer than 200,000 Americans. If left untreated, GCA can cause headaches, pain and stiffness, and even blindness.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Corticosteroids, given at first in high doses and then tapered down over several months, are “an extremely effective therapy” for GCA, says Peter A. Merkel, MD, MPH, director of the Boston University Vasculitis Center and lead author of the new study. “The critical problem is that they have significant toxicity, especially in the elderly,” he explains.

Indeed, for 53% to 86% of GCA patients, corticosteroids induce serious side effects like mood changes, weight gain, cataracts, and osteoporosis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Several clinical trials have tested the use of low-dose MTX as an adjunctive treatment for patients with new-onset GCA. But the three largest randomized, placebo-controlled trials came to different conclusions: One showed a clear benefit of using MTX in reduction of GCA relapse and reduced use of corticosteroids; one showed mixed results; and one showed no clear benefit.

These discrepancies led to “great variation within the rheumatology practice community as to the use of MTX,” says Dr. Merkel. Because MTX has its own potential side effects, including liver toxicity, bone marrow toxicity, and GI upset, many doctors were cautious about prescribing it to their elderly patients. The meta-analysis of combined data from the three studies aimed to resolve these discrepancies.

At least one author from each of the three studies was involved in the new study, which pooled comprehensive data – including the time to first relapse, time to second relapse, cumulative dose of corticosteroids, time to discontinuation of corticosteroids, and adverse events – from 161 patients. Using the original data from individual patients, rather than that published in summary tables, “provided for much more sophisticated analyses and more precise estimates of outcomes,” says Dr. Merkel.

The analysis found that after 48 weeks of treatment, patients who received MTX and corticosteroids had a 63% chance of first relapse and 22% chance of second relapse. Patients receiving a placebo and corticosteroids had a significantly higher risk of both first and second relapse – 80% and 40%, respectively.

Moreover, MTX reduced patients’ need for corticosteroids. At 48 weeks, those treated with MTX had taken an average of 842 mg less of corticosteroids than those who were treated with placebo.

The researchers speculate that the initial discrepancies among the three studies arose because of differences in the length of follow-up. The benefit of MTX only appears after 24 to 36 weeks of treatment.

Though the study supports the use of MTX as adjunctive therapy in patients with new-onset GCA, Dr. Merkel emphasizes that corticosteroids must remain “the first and most important therapy. We don’t want a single doctor to think MTX should replace them.”

Psoriatic Arthritis Patients Without Classic Atherosclerosis Risk Factors Often Have Subclinical Disease

Psoriatic arthritis (PsA) patients have an increased risk of experiencing adverse cardiovascular events, according to a study published in Arthritis Care & Research (2007;57:1074-1080).

Several previous studies have asked whether patients with PsA – like patients with RA – have an increased risk of developing cardiovascular disease and thus have a higher mortality rate than the general population. But the results of these studies differed: some found a correlation and others did not.

To answer the question more definitively, a group of Spanish researchers used non-invasive ultrasonography to determine the intima-media thickness (IMT) of the carotid arteries and the presence of carotid plaques in 59 PsA patients and 59 matched control subjects. They found that PsA patients had significantly larger IMTs than matched controls. Though plaques were more often found in the PsA patients than the controls (nine and three patients, respectively), the difference was not statistically significant.

Because the IMT of the carotid arteries directly correlates with the risk of experiencing adverse cardiovascular events, the authors of the new study say these results show that PsA patients – even those without traditional risk factors – are at greater risk of cardiovascular disease.

The study confirms for the first time “that psoriatic arthritis by itself, regardless of other factors, is associated with accelerated atherosclerosis,” says lead author Miguel A. Gonzalez-Gay, MD, PhD, of the rheumatology department at the Hospital Xeral-Calde in Lugo, Spain. He was not especially surprised by these results, as they agreed with some epidemiological data reported by Canadian researchers.

Dr. Gonzalez-Gay recommends that, like RA patients, all PsA patients receive an ultrasound to determine IMT thickness. “The technique is cheap and rapid,” he says.

Moreover, he stresses that doctors should prescribe statins to PsA patients in order to keep their LDL-cholesterol levels low. As with patients who have diabetes or coronary artery disease, he says, PsA patients should ideally maintain LDL-cholesterol levels of about 100 mg/dl, which is lower than the 140-160 mg/dl that is normal in patients who are not at risk.

Virginia Hughes is a medical journalist based in New York City.

Page: 1 2 3 | Multi-Page
Share: 

Filed under:ConditionsOther Rheumatic ConditionsPsoriatic ArthritisResearch RheumVasculitis Tagged with:A&RAC&RCardiovascular diseasegiant cell arteritis (GCA)MethotrexatePsoriatic Arthritis

Related Articles

    Two Inflammatory Conditions—Polymyalgia Rheumatica and Giant Cell Arteritis—Share Clinical Connection

    March 1, 2013

    Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) have common clinical and epidemiologic links, but they need not occur synchronously

    Updates on Giant Cell Arteritis

    March 19, 2018

    arka38 / SHUTTERSTOCK.COM SAN DIEGO—Recent research tells us more about giant cell arteritis (GCA) to help rheumatologists more accurately diagnose and effectively treat patients with this type of vasculitis. On Nov. 6 at the ACR/ARHP Annual Meeting, three experts explored the latest findings on GCA pathogenesis, diagnostic approaches, imaging modalities and growing treatment options. GCA:…

    Case Report: Giant Cell Arteritis-Related Stroke

    September 10, 2023

    Thromboembolic events are major contributors to the morbidity and mortality of patients with giant cell arteritis (GCA), but little is known about how GCA may increase the risk of ischemic strokes. GCA-related stroke is described as an ischemic cerebral infarct occurring within three to four weeks of GCA diagnosis and treatment. It occurs in 3–7%…

    Giant Cell Arteritis Challenging to Diagnose, Manage

    March 1, 2015

    Common form of primary vasculitis difficult to identify, treat, but latest research suggests potential new therapeutic targets

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences